Literature DB >> 25630346

Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study.

Polina Putrik1, Sofia Ramiro2, Andras P Keszei3, Ihsane Hmamouchi4, Maxime Dougados5, Till Uhlig6, Tore K Kvien7, Annelies Boonen8.   

Abstract

OBJECTIVES: To investigate the relationship of socioeconomic status (SES) on an individual and country level with disease activity in rheumatoid arthritis (RA) and explore the mediating role of uptake of costly biological disease-modifying antirheumatic drugs (bDMARDs) in this relationship.
METHODS: Data from a cross-sectional multinational study (COMOrbidities in RA) were used. Contribution of individual socioeconomic factors and country of residence to disease activity score with 28-joint assessment (DAS28) was explored in regression models, adjusting for relevant clinical confounders. Next, country of residence was replaced by gross domestic product (GDP) (low vs high) to investigate the contribution of SES by comparing R(2) (model fit). The mediating role of uptake of bDMARDs in the relationship between education or GDP and DAS28 was explored by testing indirect effects.
RESULTS: In total, 3920 patients with RA were included (mean age 56 (SD 13) years, 82% women, mean DAS28 3.7 (1.6)). After adjustment, women (vs men) and low-educated (vs university) patients had 0.35 higher DAS28. Adjusted country differences in DAS28, compared with the Netherlands (lowest DAS28), varied from +0.2 (France) to +2.4 (Egypt). Patients from low GDP countries had 0.98 higher DAS28. No interactions between individual-level and country-level variables were observed. A small mediation effect of uptake of bDMARDs in the relationship between education and DAS28 (7.7%) and between GDP and DAS28 (6.7%) was observed.
CONCLUSIONS: Female gender and lower individual or country SES were independently associated with DAS28, but did not reinforce each other. The association between lower individual SES (education) or lower country welfare (GDP) with higher DAS28 was partially mediated by uptake of bDMARDs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  DAS28; Epidemiology; Rheumatoid Arthritis

Mesh:

Substances:

Year:  2015        PMID: 25630346     DOI: 10.1136/annrheumdis-2014-206737

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  23 in total

1.  Increased risk of rheumatoid arthritis in patients with migraine: a population-based, propensity score-matched cohort study.

Authors:  Yi-Chia Wang; Ya-Ping Huang; Mei-Ting Wang; Hsin-I Wang; Shin-Liang Pan
Journal:  Rheumatol Int       Date:  2016-11-14       Impact factor: 2.631

2.  Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study.

Authors:  Katrine Løppenthin; Bente Appel Esbensen; Mikkel Østergaard; Rikke Ibsen; Jakob Kjellberg; Poul Jennum
Journal:  Clin Rheumatol       Date:  2016-10-25       Impact factor: 2.980

3.  Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Authors:  Patrick Durez; Karel Pavelka; Maria Alicia Lazaro; Abraham Garcia-Kutzbach; Robert J Moots; Howard Amital; Marinella Govoni; Nathan Vastesaeger
Journal:  Clin Rheumatol       Date:  2018-04-02       Impact factor: 2.980

4.  Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines.

Authors:  Jin-Wuk Hur; Jung-Yoon Choe; Dong-Wook Kim; Hyun Ah Kim; Sang-Hyon Kim; Wan-Uk Kim; Yun Sung Kim; Hye-Soon Lee; Sang-Heon Lee; Sung-Hwan Park; Won Park; Yong-Beom Park; Chang-Hee Suh; Seung-Cheol Shim; Yeong-Wook Song; Bo Young Yoon; Dae Young Yu; Dae Hyun Yoo
Journal:  Rheumatol Int       Date:  2015-09-05       Impact factor: 2.631

Review 5.  Access to an optimal treatment. Current situation.

Authors:  Manuel F Ugarte-Gil; Adriana M R Silvestre; Bernardo A Pons-Estel
Journal:  Clin Rheumatol       Date:  2015-07-19       Impact factor: 2.980

6.  Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment.

Authors:  Peter C Taylor; Rieke Alten; Juan J Gomez-Reino; Roberto Caporali; Philippe Bertin; Emma Sullivan; Robert Wood; James Piercy; Radu Vasilescu; Dean Spurden; Jose Alvir; Miriam Tarallo
Journal:  RMD Open       Date:  2018-03-17

7.  Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.

Authors:  Cynthia S Crowson; Silvia Rollefstad; George D Kitas; Piet L C M van Riel; Sherine E Gabriel; Anne Grete Semb
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

8.  Area of Residence and Socioeconomic Factors Reduce Access to Biologics for Rheumatoid Arthritis Patients in Romania.

Authors:  Cătălin Codreanu; Claudiu C Popescu; Corina Mogoşan
Journal:  Biomed Res Int       Date:  2018-05-08       Impact factor: 3.411

9.  Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study.

Authors:  Hanna W van Steenbergen; Roula Tsonaka; Tom W J Huizinga; Annelies Boonen; Annette H M van der Helm-van Mil
Journal:  RMD Open       Date:  2015-03-04

10.  Prevalence of arthritis according to age, sex and socioeconomic status in six low and middle income countries: analysis of data from the World Health Organization study on global AGEing and adult health (SAGE) Wave 1.

Authors:  Sharon L Brennan-Olsen; S Cook; M T Leech; S J Bowe; P Kowal; N Naidoo; I N Ackerman; R S Page; S M Hosking; J A Pasco; M Mohebbi
Journal:  BMC Musculoskelet Disord       Date:  2017-06-21       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.